Podcasts about veklury

Got Health Questions or Comments?

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss how to optimize the use of COVID-19 antivirals and how to navigate drug-drug interactions between COVID-19 treatments and a patient's home medications. Their discussion includes:Current COVID-19 landscapeCOVID-19 testing and vaccination recommendationsTreatment guidelines and antiviral options for nonhospitalized adults with COVID-19Resources for assessing and managing COVID-19 antiviral-related drug-drug interactionsAnswers to learners' most pressing questionsPresenters:Renslow Sherer, MDProfessor of MedicineSection of Infectious Diseases and Global HealthUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of PharmacyEmory University Hospital MidtownAtlanta, GeorgiaSlideset: https://bit.ly/4c6kwbJDownloadable resource:https://bit.ly/49rofP6Full program: https://bit.ly/3P16TR8Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.

Guest host Scott Schara visits with Dr. Bryan Ardis. In early 2020 Bryan lost his Father-in-law because of ill-advised hospital protocols. Since that time, he has been on a relentless mission to help educate the public about the hidden dangers in many of our "institutes of health". His focus is on medical freedom, education, and waking up the world with the truth of natural immunity and the miracle healing power of all things natural. Dr. Ardis explains how we've been lied to and offers solutions that work and are not part of the medical programming. He offers his advice on how to protect ourselves from all future attempts to kill us. Sidenote: We discuss Remdesivir. Watch out for the Veklury and Paxlovid, which is how the medical industry is now hiding the use of Remdesivir. Catch Stand Up For The Truth on YouTube and Rumble !

Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults.

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, Tracey Piparo, PA-C, and Renslow Sherer, MD, discuss cases of nonhospitalized patients with COVID-19, including:Young, healthy patient with no risk factorsYoung, healthy patient with risk factorsOlder patient with immunocompromiseOlder patient with renal dysfunctionPatient experiencing hypoxia Presenters: Tracey Piparo, PA-C Department of Palliative Medicine RJWBarnabas New Brunswick, New Jersey Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois To download the slides: bit.ly/44cgH0qTo view the full online program: https://bit.ly/4201xcO

In this episode, Vikramjit Mukherjee, MD, and Cameron Smith, MPAS, PA-C, answer audience questions on how best to care for hospitalized patients with COVID-19 from a live, virtual question and answer webinar. This episode includes expert insights on:Supportive care management such as oxygen support, glycemic control, and anticoagulationEscalation of therapy in patients with worsening oxygen requirementsUse of remdesivir in patients with renal dysfunctionBrief commentary on long COVIDPresenters:Vikramjit Mukherjee, MDAssistant Professor  Division of Pulmonary, Critical Care, & Sleep Medicine  New York University School of Medicine  DirectorMedical Intensive Care UnitBellevue HospitalNew YorkCameron Smith MPAS, PA-CLead Advanced Practice ProviderMedical Intensive Care UnitBellevue HospitalNew York Health and Hospitals  New York, New YorkContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc.bit.ly/3z52c00

Carolyn”CC” Blakeman Media Director and Task Force Coordinator at FormerFedsGroup & Attorney Jamie Scher join...

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 treatments and the possibility for antiviral resistance, including:Treatment resistance mechanismsCOVID-19 testingCOVID-19 treatments, including antivirals and monoclonal antibodiesPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite DirectorCOVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

In this episode, Jason Gallagher, PharmD, and Emily Heil, PharmD, MS, BCIDP discuss landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound phenomenon, including:  EPIC-HR study of nirmatrelvir plus ritonavirPINETREE study of remdesivirMOVe-OUT and Panoramic studies of molnupiravirCOVID-19 rebound in treated and untreated patientsPresenters:Jason Gallagher, PharmDClinical ProfessorSchool of PharmacyTemple UniversityClinical Pharmacy SpecialistInfectious DiseasesTemple University HospitalPhiladelphia, PennsylvaniaEmily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of Pharmacy Practice and ScienceUniversity of Maryland School of PharmacyInfectious Diseases Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, Maryland 

A Agência Nacional de Vigilância Sanitária ampliou o uso do medicamento Remdesivir para tratamento pediátrico contra a covid-19. O antiviral injetável de uso hospitalar é vendido no Brasil pelo nome comercial Veklury. A Anvisa também aprovou nesta segunda-feira (21), a venda de Paxlovid para farmácias e hospitais particulares do país. O medicamento é de uso adulto para tratar covid-19 e a venda exige prescrição médica.

In his weekly clinical update Dr. Griffin discusses the four things to know about RSV, the burden of respiratory syncytial virus in healthy term-born infants in Europe, the diagnostic accuracy of rapid diagnostic tests for Ebola virus disease, evaluating the accuracy of self-collected swabs for the diagnosis of monkeypox, tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations, acute and postacute sequelae associated with SARS-CoV-2 reinfection, clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients, effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy, maternal antibody response and transplacental transfer following SARS-CoV-2 infection or vaccination in pregnancy, impact of community masking on COVID-19, Lifting Universal Masking in Schools – Covid-19 Incidence among Students and Staff, systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients, comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in patients in the community, early adoption of anti–SARS-CoV-2 pharmacotherapies among us veterans with mild to moderate COVID-19, evaluation of viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants, monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy, twice daily oral zinc in the treatment of patients with COVID-19, cognitive deficits in long Covid-19, severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration, and long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Four things to know about RSV (Gates Foundation) The burden of RSV in healthy term-born infants in Europe (The Lancet) Diagnostic accuracy of rapid tests for Ebola (CMI) Accuracy of self-collected swabs for diagnosis of Monkeypox (CID) Tecovirimat is effective against human monkeypox virus in vitro (Nature) Acute and postacute sequelae associated with SARS-CoV-2 reinfection (NatureMedicine) SARS-CoV-2 infection and recovery in lung transplant recipients (Transplant Infectious Diseases) Effectiveness of third COVID-19 vaccination during pregnancy (Nature Communications) Maternal antibody response and transplacental transfer following infection or vaccination (CID) Impact of community masking on COVID-19 (Science) Lifting universal masking in schools (NEJM) Bebtelovimab fact sheet for providers (FDA) Effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 (medRxiv) Effectiveness of Sotrovimab and Molnupiravir for prevention of severe COVID-19 outcomes (BMJ) Early adoption of Anti–SARS-CoV-2 pharmacotherapies among US veterans (JAMA) PAXLOVID patient eligibility screening checklist (FDA) Viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants (medRxiv) Monoclonal antibodies for treatment of SARS-CoV-2 during pregnancy (Annals of Internal Medicine) Remdesivir fact sheet for providers (Veklury)  Twice daily oral zinc in the treatment of patients with COVID-19 (CID)  Cognitive deficits in long COVID-19 (NEJM) Severe Neuro-COVID associated with peripheral immune signatures, autoimmunity and neurodegeneration (Nature Communications) Long-lasting symptoms after an acute COVID-19 Infection (JAMA) Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 955 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:COVID-19 vaccines, including omicron BA.1 bivalent boosterRisk factors for breakthrough COVID-19 infectionsCOVID-19 diagnostics, including digital droplet PCRCOVID-19 therapeutics, including:Nirmatrelvir plus ritonavirTixagevimab plus cilgavimabBaricitinibTocilizumabInhaled interferon β-1aCOVID-19 therapeutics and outcomes in patients with immunocompromiseLong COVIDPresenters:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCPaul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the downloadable slideset at:http://bit.ly/3gkJI67Link to full program:http://bit.ly/3TSVthM

In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses, antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot, immunogenicity of bivalent mRNA vaccine boosters, long-term gastrointestinal sequelae following COVID-19, evaluation of an automated text message–based program to reduce use of acute health care resources after hospital discharge, and how in adults with COVID-19, melatonin was assessed for effects on inflammatory markers, clinical signs and symptoms, and mortality. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Influenza incidence and vaccine effectiveness (CDC) Nirsevimab for prevention of RSV (NEJM) Severe Monkeypox in hospitalized patients (CDC) Reinfections with different SARS-CoV-2 Omicron subvariants (CDC) Impact of community masking on COVID-19 (Science) Vaccine elicits protective immunity against sarbecoviruses (Science) Antibody responses to bivalent mRNA vaccine booster shot (Biorxiv) Immunogenicity of bivalent mRNA vaccine boosters (Biorxiv) Long-term gastrointestinal sequelae following COVID-19 (CGH) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Evaluation of an automated text message–based program (JAMA) Melatonin assessed for effects on inflammatory markers in COVID patients (Heliyon) PAXLOVID patient eligibility screening checklist (FDA) Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 951 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses the prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic, severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters, and how successful immunomodulators for treatment of COVID-19 have opened the pathway for comparative trials. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support MicrobeTV with a Spike t-shirt at Vaccinated.US Prediction of upcoming global infection burden of Influenza (The LANCET) Severe COVID-19 outcomes after full vaccination (The LANCET) Successful immunomodulators for treatment of COVID-19 (CMI) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) PAXLOVID patient eligibility screening checklist (FDA) Dr. Griffin's treatment guide (pdf) Contribute to Floating Doctors fundraiser at PWB Letters read on TWiV 947 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Research assistant position with Amy Rosenfeld (pdf) Support MicrobeTV with a Spike t-shirt at Vaccinated.US A healthcare-associated infection with monkeypox virus (OFID) Air and surface sampling for monkeypox virus (The Lancet) Misrepresentation & nonadherence in COVID-19 public health measures (JAMA) Tolerability and immunogenicity of a COVID-19 vaccine (The Lancet) PAXLOVID patient eligibility screening checklist (FDA) Evaluation of symptomatic disease rebound following PAXLOVID (CID) Outpatient treatment with Remdesivir in patients at high risk (OFID) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Molnupiravir as early treatment for adults with COVID-19 (SSRN) Outcomes among confirmed cases and matched comparison group in long-COVID (Nature) Dr. Griffin's treatment guide (pdf) Contribute to Floating Doctors fundraiser at PWB Letters read on TWiV 945 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses high points of the multi-national monkeypox outbreaks, monkeypox virus genome mutations, possible occupational infection of healthcare workers with monkeypox virus, rates of monkeypox cases by vaccination status, protection of SARS-CoV-2 infection against reinfection, Paxlovid significantly reduces COVID-19 hospitalizations and deaths, and rebound in COVID19 with and without Paxlovid treatment. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Research assistant position with Amy Rosenfeld (pdf) Support MicrobeTV with a Spike t-shirt at Vaccinated.US Multi-National Monkeypox outbreak (CDC) Mutation of the Monkeypox Virus (Nature) Occupational infection of Healthcare workers with Monkeypox (CDC) Rates of Monkeypox cases by vaccination status (CDC) Protection of SARS-CoV-2 natural infection against reinfection (CMI) PAXLOVID patient eligibility screening checklist (FDA) Paxlovid reduces COVID19 hospitalizations & deaths (EPIC) Paxlovid rebound in COVID19 (NEJM) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Dr. Griffin's treatment guide (pdf) Contribute to Floating Doctors fundraiser at PWB Letters read on TWiV 944 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses, further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave, effectiveness of Molnupiravir in high risk patients, and primary care and a distinct symptom pattern for long COVID. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Research assistant position with Amy Rosenfeld (pdf) Support MicrobeTV with a Spike t-shirt at Vaccinated.US Increase in Acute Respiratory illnesses among children and adolescents (CDC) Estimates of Monkeypox incubation period, generation time, reproduction number (CDC) Rapid increase in suspected SARS-CoV-2 reinfections (CDC) Infection prevention and control recommendations for healthcare providers (CDC) SARS-CoV-2 attack rate in vaccinated and unvaccinated household contacts (CDC) Breakthrough Infection by variants elicited immune response comparable to vaccine (JID) Interval between prior SARS-CoV-2 infection and booster vaccination impacts (CELL) Humoral immunity evasion of BA.4 and BA.5 subvariants (The Lancet) Outpatient Remdesivir prevents severe disease in organ transplant recipients (Am J Transplant)  PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Effectiveness of Molnupiravir in high risk patients (CID) Update on Long COVID for primary care (BMJ) Distinct symptom pattern emerges for COVID-19 long-haul (Scientific Reports) Dr. Griffin's treatment guide (pdf) Contribute to Floating Doctors fundraiser at PWB Letters read on TWiV 941 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses detection of a highly divergent type 3 vaccine-derived poliovirus in a child with a severe primary immunodeficiency disorder, severe respiratory illnesses associated with rhinoviruses and/or enteroviruses including EV-D68, effects of vaccination and previous infection on Omicron infections in children, COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, effectiveness of COVID-19 vaccines over time prior to Omicron emergence in Ontario, Canada, nasal IgA wanes 9 months after hospitalization with COVID-19 and is not induced by subsequent vaccination,  resistance of SARS-CoV-2 Omicron subvariant BA.4.6 to antibody neutralization, persistent circulating SARS-CoV-2 spike associated with post-acute COVID-19 sequelae, and impact of COVID-19 vaccination on the risk of developing long-covid and on existing long-covid symptoms. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Detection of poliovirus in immunosuppressed child (CDC) Severe respiratory illnesses associated with rhinoviruses and/or enteroviruses (CDC) Effects of vaccination and previous Omicron infection in children (NEJM) COVID-19 hospitalizations among vaccinated and unvaccinated adults (JAMA) Effectiveness of vaccines prior to Omicron (IDSA) Nasal iga wanes 9 months after COVID hospitalization (medRxiv) Resistance of Omicron subvariant to antibody neutralization (BioRxiv) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) SARS-CoV-2 spike is associated with post-acute sequelae (IDSA) Impact of vaccination on the risk of developing long-COVID (The Lancet) Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 936 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses variant influenza virus infections: recommendations for identification, treatment, and prevention for summer and fall 2022, low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals, using the right tools at the right time for SARS-COV-2 infection, onset and window of SARS-COV-2 infectiousness and temporal correlation with symptom onset, transmission of SARS-COV-2: a review of viral, host, and environmental factors, antibody persistence and safety through 6 months after heterologous orally aerosolized Ad5-nCoV in individuals primed with two-dose vaccine, timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients, administration of anti–SARS-COV-2 monoclonal antibodies after US Food and Drug Administration deauthorization, and clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode 2022 recommendations for Influenza infections (CDC) Low levels of monkeypox neutralizing antibodies after vaccination (medRxiv) Using the right tools during SARS-CoV-2 infection (ESMED) Onset and window of SARS-CoV-2 infectiousness with symptom onset (The LANCET) Transmission of SARS-COV-2 (ACP Journals) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Administration of anti–SARS-COV-2 monoclonal antibodies (JAMA) Clinical and genetic risk factors for thromboembolism (JAMA) Administration of tocilizumab improves outcomes (PLOS One) Antibody persistence and safety through 6 months (medRxiv) Improve risk score for thromboembolism (mdCalc) Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 934 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses vaccine effectiveness against influenza illness in children, clinical manifestations of infection with poliovirus, spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice, concordance of SARS-CoV-2 results in self-collected nasal swabs vs swabs collected by health care workers in children and adolescents, probable animal-to-human transmission of SARS-CoV-2 causing a pet shop-related outbreak, laboratory-confirmed COVID-19–associated hospitalizations among adults during BA.2 variant, SARS-CoV-2 specific T-cells and antibodies, Nirmatrelvir use and outcomes during the Omicron surge, real-world effectiveness of early Molnupiravir or Nirmatrelvir–ritonavir in hospitalized patients, and distinguishing features of long COVID. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Vaccine effectiveness against Influenza illness in children (CID) Clinical manifestations of infection with Polio (JAMA) Characteristics of deaths among fully vaccinated persons with Coronavirus (CID) Spike protein attenuation of Omicron Variant in lab mice (Cell Reports) Concordance of SARS-CoV-2 results in nasal swabs self-collected vs healthcare collected (JAMA) Probable animal-to-human transmission of Sars-Cov-2 (CID) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) COVID-19–associated hospitalizations among adults during BA.2 variant (CDC) Sars-Cov-2 specific T-cells and antibodies (CID) Nirmatrelvir use and outcomes during the Omicron surge (NEJM) Effectiveness of early Molnupiravir or Nirmatrelvir–Ritonavir in hospitalized patients (The Lancet) Distinguishing features of long COVID (medRxiv) Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 932 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses antibody response against nonpoliovirus enteroviruses, clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain, object and surface contamination with monkeypox virus, monkeypox virus infection in humans across 16 countries, clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection, compassionate use of Tecovirimat for the treatment of monkeypox infection, monitoring of Pfizer-BioNTech vaccine among children, Pfizer and BioNTech announce updated vaccine data supporting efficacy in children, direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer, Pfizer and BioNTech submit application for bivalent vaccine, and Oral Nirmatrelvir and Ritonavir in non-hospitalized vaccinated patients with COVID-19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Antibody response against nonpoliovirus enteroviruses (ASM) Clinical presentation of Monkeypox cases in Spain (The Lancet) Object and surface contamination with Monkeypox virus infection (CDC) Environmental persistence of Monkeypox virus (Emerg Inf Dis) Monkeypox virus infection across 16 countries (NEJM) Clinical characteristics of hospitalization patients with Monkeypox (CMI) Usage of Tecovirimat for treatment of Monkeypox infection (JAMA) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Monitoring of Pfizer-BioNTech vaccine among children (CDC) Pfizer and BioNTech announce updated vaccine data (Pfizer) Capture of RBD enables point of care assessment (Science Direct) Pfizer and BioNTech submit application for bivalent vaccine (Pfizer) PAXLOVID in non-hospitalized vaccinated patients  Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 930 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses the public health response to a polio case in a unvaccinated NY state resident, human to dog transmission of monkeypox virus, Tecovirimat and the treatment of monkeypox, detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium, what to do if you are exposed to SARS-CoV-2 and isolation and precautions for people with COVID-19, risk of SARS-CoV-2 infection in health care workers, effectiveness of HEPA filters at removing infectious SARS-CoV-2 from the air, Pfizer reports additional data on Paxlovid, hospitalization encounters for infection after Paxlovid, a randomized trial of Metformin, Ivermectin, and Fluvoxamine, and readmissions, post-discharge mortality and sustained recovery among patients admitted to hospital with COVID-19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Response to Polio case in an unvaccinated person in New York (CDC) Human to dog transmission of Monkeypox virus (The Lancet) Tecovirimat for the treatment of Monkeypox (NEJM) Detection of asymptomatic Monkeypox among Belgian men (Nature Medicine) Exposure to disease and precautions (CDC) Risk of infection in healthcare workers (JAMA) Effectiveness of HEPA filters (ASM) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Pfizer reports additional data on PAXLOVID (Pfizer) Hospitalization encounters for infection after PAXLOVID (CDC) Trial for Metformin, Ivermectin, and Fluvoxamine (NEJM) Readmission, post-discharge mortality, recovery among patients (IDSA) Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 928 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses guidance for prevention and treatment of monkeypox, post-infectious symptoms among children and adolescents, profiling post-infectious syndromes of different variants, comparison of vaccine Ankara vs intradermal routes of administration, infection in vaccinated individuals treated with or without PAXLOVID, duration of symptoms with positive rapid antigen after infection, epidemiologic characteristics of monkeypox, and sequelae of post-acute infection. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Guidance for prevention & treatment of Monkeypox (CDC) Post-infection symptoms among children and adolescents (CDC)  Profiling post-infection syndromes in different variants (medRxiv) Comparison  of vaccinia Ankara (MVA) vs intradermal routes of administration (NIH) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Infection in vaccinated individuals treated with or without PAXLOVID (medRxiv) Duration of symptoms with positive rapid antigen after infection (J Virological Methods) Epidemiologic characteristics of Monkeypox (CDC) Sequelae of post-acute infection (ScienceDirect)  Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 926 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses Tecovirimat for treatment of monkeypox, the safety and acceptance of vaccination after multisystem inflammatory syndrome, variants in solid organ transplant recipients, masks for prevention of respiratory virus infections, pre-exposure prophylaxis with Evusheld, the association between Evusheld administration and infection,  if repeat administration of casirivimab and imdevimab is well-tolerated, viral and symptom rebound in untreated infection, extended Remdesivir infusion for persistent infection, Baricitinib in patients admitted with infection, and cognitive impairment 13 months after hospitalization. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Armchair Expert with Malcolm Gladwell Tecovirimat for treatment of monkeypox (OFID) Safety and acceptance of vaccination after MIS (JPID) Is variant less virulent in solid organ transplant recipients (Transplant Infectious Disease) Masks for prevention of respiratory virus infections (Annals of Internal Medicine) Pre-exposure prophylaxis with Evusheld (CMI) Association between Evusheld administration and infection (CID) Repeat administration of casirivimab and imdevimab well-tolerated (ISID) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Viral and symptom rebound in untreated infection (medRxiv) Extended Remdesivir infusion for persistent infection (OFID) Baricitinib in patients admitted with infection (The Lancet) Cognitive Impairment 13 months after hospitalization (OFID) Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 924 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses monkeypox infection in humans across 16 countries, pregnancy outcomes after SARS-CoV-2 infection by trimester, vaccination intent and belief, antiviral drug treatment for non-severe disease, the association of smoking with infected hospitalized patients, the association of Paxlovid on negative conversion rates among high-risk patients with COVID-19, safety and efficacy of Molnupiravir, usage of enoxaparin for primary thromboprophylaxis, statin and aspirin as therapy in infected patients, post-COVID-19 conditions among children 90 days after SARS-CoV-2 Infection, and symptoms and risk factors for long COVID in non-hospitalized adults. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monkeypox infection in humans (NEJM) Pregnancy outcomes after infection (PLOS ONE) Vaccination intent and belief (Emerging Infectious Diseases) Antiviral drug treatment for non-severe disease (CMAJ) Smoking association with infected hospitalized patients (PLOS ONE) Impact of Paxlovid on negative conversion rates (CID) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Safety and efficacy of Molnupiravir (Journal of Medical Virology) Enoxaparin for primary thromboprophylaxis (OVID) Statin and aspirin as therapy in infected patients (BMC) Post-infection conditions among children (JAMA) Symptoms and risk factors for long-term effects (Nature Medicine)  Contribute to FIMRC fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 922 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv  

In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC's recommendation of Novavax's COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Variant vaccine boosters trial (medRxiv) Novavax triggers neutralization of variant sub-lineages (bioRxiv) CDC recommends Novavax (CDC) Paxlovid in patients who are immunocompromised and hospitalized (The Lancet) Inhaled Fluticasone for outpatient treatment (medRxiv) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Contribute to FIMRC fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 921 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #123, Dr. Griffin discusses rapid diagnostic testing in response to the monkeypox outbreak, leading causes of death in the US during the COVID-19 pandemic, antibody evasion by subvariants, broadly-neutralizing antibodies against emerging variants, factors associated with severe outcomes among hospitalized immunocompromised adults, measurement of the burden of hospitalizations during the pandemic, parental vaccine hesitancy in diverse communities, evaluating saliva sampling to improve access to diagnosis in low-resource settings, oral sabizabulin for high-risk hospitalized adults, lower-risk of multisystem inflammatory syndrome in children, and neurovascular injury with complement activation and inflammation during infection. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monkeypox outbreak rapid testing response (CDC) Leading causes of death during pandemic (JAMA) FDA recommends vaccine update (FDA) Antibody evasion by subvariants (Nature) Broadly-Neutralizing antibodies against variants (Frontiers in Immunology) Severe outcomes factors in immunocompromised adults (CDC) Measurement of the burden of hospitalizations (OFID) Vaccine hesitancy among parents (Academic Pediatrics)  PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Saliva evaluation to improve diagnostics (ASTMH) Oral Sabizabulin for high-risk adults (NEJM) Lower risk of MIS-C in children (CID) Neurovascular injury during infection (Brain) Paul Offit on TWiV 917 Contribute to FIMRC fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 918 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

AJ DePriest, founder of the Tennessee Liberty Network, warns that the Centers for Medicare and Medicaid Services (CMS) are involved in the destruction of American patients' rights by enforcing government agencies' lethal Covid protocols. In this second exclusive conversation with AJ, a federal policy and legislation analyst for over three decades, we will uncover the lucrative financial incentives that motivate hospitals to treat Covid patients with deadly drugs like Remdesivir or it's market name Veklury. The total average reimbursement that hospitals receive for each Covid admission is a staggering $293,000. To fight back against receiving potentially deadly hospital sedatives, drugs, and ventilators, AJ advises early treatment, as well as finding a solid doctor who will prescribe safe and effective medication.    TAKEAWAYS CMS set up Diagnosis-Related Groups, or DRGs, to reimburse hospitals at a high rate Parents need to make sure their kids' schools aren't using extremely toxic Triethylene Glycol in their HVAC systems The CMS is directly involved in issuing waivers that have allowed hospitals to treat patients without their consent Covid protocols serve a two-fold purpose: to eliminate those who are considered a “drain” on society and to flood hospitals with funding

In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Tixagevimab-Cilgavimab for infection prevention (NEJM) Ivermectin for outpatient infection treatment (medRxiv) Symptom rebound after PAXLOVID treatment (IDSA) Bamlanivimab minimally impacts immune response to vaccination (Sci Transl Med) In-hospital morality among infected patients (IDSA) Casirvimab/Imdevimab & Remdesivir for infected B-cell depleted patients (IDSA) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Residual viral antigen in patients post infection (IDSA) Rheumatic symptoms following infection (IDSA) Contribute to FIMRC fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 910 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #118, Dr. Griffin discusses management of hair loss after infection, FDA announcements on vaccine schedule and recommendations, Moderna announcement on bivalent booster candidate, association between vaccination and infection during pregnancy, population-level implications of Israel's booster campaign, PAXLOVID outcomes during recent infection surge, efficacy and safety of Tixagevimab-cilgavimab, diagnostic accuracy of infection by canines, efficacy of colchicine in hospitalized patients, and factors associated with hospital readmission.   Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Management of hair loss after infection (NIH) FDA announces vaccine schedule meeting (FDA) FDA advisory committee recommends NOVAVAX vaccine (Novavax) Moderna announces bivalent booster candidate (Moderna) Association of vaccination and infection during pregnancy (JAMA) Implications of Israeli booster campaign (Science Translational Medicine) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) PAXLOVID outcomes during infection surge (Research Square) Efficacy and safety of Tixagevimab–cilgavimab (The Lancet) Diagnostic accuracy of infection by canines (PLOS ONE) Efficacy of colchicine in hospitalized patients (Nature) Factors associated with readmission (IDSA)  Contribute to FIMRC fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 908 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #117, Dr. Griffin discusses duration of virus shedding, association between pre-exposure to steroids and infection outcome, post-infection subtypes, rehabilitation for post-acute infection, Tixagevimab/Cilgavimab for infection prevention, antibody prophylaxis and vaccination in kidney transplant recipients, remdesivir and bebtelovimab fact sheets for providers, the updated guidelines on treatment with Famotidine, Paxlovid rebound symptom characterizations, antigen test positivity duration, viral dynamics of variants and isolation, association of inflammation in CS fluid, and transmission dynamics in Ghana. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Duration of virus shedding (NIH) Association between pre-exposure to steroids and infection outcome (CMI) Post-infection subtypes (medRxiv) Rehabilitation for post-acute infection syndrome (MDPI) Tixagevimab/Cilgavimab for infection prevention (medRxiv) Antibody prophylaxis & vaccination in kidney transplant recipients (Kidney International) Guideline on treatment with Famotidine (IDSA)  Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) PAXLOVID rebound symptom characterization (medRxiv) Antigen test positivity duration (medRxiv) Viral dynamics of variants and isolation (NIH)  Association of inflammation in CS fluid (JAMA) Transmission dynamics in Ghana (ASTMH)  Contribute to FIMRC fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 905 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #115, Dr. Griffin discusses croup association with infection surge, rhinovirus co-circulation in children, shedding following vaccination, high vaccine efficacy in children 6 mo-5 yr, vaccine protection for hospitalized patients, convalescent plasma as post-exposure prophylaxis, real-world effectiveness of PAXLOVID, effectiveness of PAXLOVID in reducing hospitalization, infection rebound after PAXLOVID, relapse of symptomatic infection after PAXLOVID, remdesivir and bebtelovimab fact sheets for providers, guidelines on usage of anticoagulation drugs, long covid symptoms after vaccination, excess morality in MA, infection sequelae and immunity, and post infection conditions among adults. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Croup association with infection surge (PIDS) Rhinovirus co-circulation in children (Science Direct) Infection shedding following vaccination (MedRxiV) High vaccine efficacy in children 6 months to 5 years (Pfizer) Protection of vaccine against hospitalized patients (IDSA) Convalescent plasma as post-exposure prophylaxis (IDSA) Real-world effectiveness of PAXLOVID in Hong-Kong (MedRxiV) Effectiveness of PAXLOVID in reducing hospitalization (The Lancet) Infection rebound after PAXLOVID (CDC) Relapse of symptomatic infection after PAXLOVID (Research Square) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Guidelines on usage of anticoagulation drugs (ASH) Long covid symptoms after vaccination (BMJ) Excess morality in Massachusetts (JAMA) Infection sequelae and immunity (Annals of Internal Medicine) Post infection conditions among adults (CDC) Contribute to FIMRC fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 903 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Limited cross-variant immunity without vaccination (Nature) EUA for boosters in 5-11 year olds (FDA) Stages of COVID-19 (AIDS Rev) B.1.1.529 attack rate in Australia (JID) Scent dogs (BMJ) Does Omicron affect pets? (CVMBS News) Paxlovid eligibility checklist (FDA) Supratherapeutic tacrolimus with nirmatrelvir/ritonavir (Op For Inf Dis) Is longer Paxlovid needed? (Reuters) How about Veklury? (Gilead) Fluvoxamine declined (FDA) Antigen positivity after isolation (MMWR) Inflammasome activation drives COVID-19 pathology (TWiV 900, Nature) PASC and viral antigen persistence in gut (Gastroenterol) GI symptoms and fecal shedding (Med) Contribute to ASTMH fundraiser at PW Dr. Griffin's treatment guide (pdf) Letters read on TWiV 901 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

This week: USPSTF recommendations on aspirin use to prevent cardiovascular disease; Veklury indication expanded; Accupril Lots recalled; Legal action on counterfeit HIV medication; And the White House releases plan to tackle the overdose epidemic.

Additional resources OHA COVID-19 vaccine website: covidvaccine.oregon.gov OHA Facebook  Safe+Strong website Ask a Black Doctor on The Numberz REACH webpage and REACH Facebook Treatments for COVID-19 Q1: I have heard that some people can get treated for COVID-19. What treatments are available and how are they different from vaccines? Yes – treatments for COVID-19 are available for some people. Some treatments are given in the hospital, some are infusions and some are pills you can take at home. They are all in short supply and currently available to people who are high risk of severe disease.  Vaccines introduce your immune system to a protein from the virus, allowing you to build up antibodies without being infected. Vaccination can also boost any natural immunity a person may have from being previously infected.  When somebody with sufficient antibodies is exposed to COVID-19, they immediately fend off the virus, which prevents infection. As antibody levels drop, the virus may be able to infect the person but the immune system still has a decent chance to fight COVID-19 and prevent severe infection.  Booster shots rebuild antibodies quickly, within a few days, even quicker than the original vaccination. This rapid rebuild also happens when an unvaccinated person previously infected with the COVID-19 virus gets their first vaccination. So be sure to get vaccinated and boosted, even if you have previously been infected with COVID-19. Treatments do not replace vaccination, which remains the most important step we can take to protect ourselves and our loved ones.  If someone can't get vaccinated, there is a treatment available that helps the body fight the virus that causes COVID-19.  Treatment for COVID-19 must take place shortly after someone has tested positive. If you've tested positive for COVID or have symptoms, contact your doctor right away. Q2: Someone was telling me about the federal Test to Treat program. Is this a program for everyone? The Test to Treat program connects people that are at high risk of severe illness from COVID-19 with the right treatment. It provides people a place to go to get tested, receive a prescription for a treatment, and fill that prescription all at one location. The program is intended for people that do not have a doctor or who cannot easily get in to see their doctor. However, anyone can receive treatment at a Test to Treat site. To participate, a person can use the Test to Treat Locator to find a site, or call 1-800-232-0233. These sites receive their therapeutics from the federal government. OHA is working on adding additional sites that fit federal criteria to be a Test to Treat site.   Q3: If treatments support defense against COVID-19, why aren't they available to everyone? There a few reasons why treatments are not available to everyone. First, vaccines have proven to be the best defense against COVID-19. Get vaccinated and then boosted. Also, don't forget your flu shot. Secondly, because of nationwide shortages, treatments are not widely available. Finally, it is all based on eligibility. A healthcare provider determines eligibility based on your medical profile. They will consider things like if you cannot get vaccinated due to health conditions or if you had a bad reaction to the vaccine or if you need additional treatment due to a weakened immune system. Only a healthcare provider can assess if you are eligible. Q3: Are treatments safe?  Depending on your medical history, certain treatments are not recommended. To determine which treatment is right for you, consult your doctor. You should also always check that your information is from a trusted source. If you have questions about any medication, contact the FDA's Division of Drug Information at 301-796-3400 or druginfo@fda.hhs.gov. Q5: What are the names of the FDA approved or authorized treatments and once I take them, how do they work in my body to fight COVID-19? The FDA has authorized two oral antiviral medications, one from Pfizer named Paxlovid. The other from Merck named Molnupiravir. With either one, they must be taken as soon as possible after a positive COVID-19 test and within the first five days of symptoms to be effective.  Paxlovid works by stoping the replication of the COVID-19 virus in the body by binding to an enzyme that disrupts the virus' ability to mutate and keeps certain viral proteins from forming correctly.   Molnupiravir interrupts replication of the virus' genetic material by introducing mutations. As the virus copies itself, it gets so mutated that it can no longer function.   The same thing happens with the FDA approved antiviral drug Remdesivir, known as Veklury, it also acts on the virus' genetic material, blocking its ability to mutate. It is administered by injection into the vein through an IV. Monoclonal antibodies (mAbs) are authorized for use to treat COVID-19. They work by mimicking the antibodies your body produces in response to a virus. These molecules are produced in a laboratory and they work to block the COVID-19 virus from entering your cells. Monoclonal antibody treatment is a fluid given using a needle either into a vein (infusion) or under the skin (subcutaneously). Your healthcare provider or the site where you will be getting treatment will explain which treatment you will get. For both procedures, needles are used by a trained medical professional. If you are unvaccinated, you should wait 90 days after your treatment to get the vaccine. Regen-Cov, Sotrovimab, Bebtelovimab and Evusheld are all monoclonal antibodies. Sotrovimab is effective against infection by the  Omicron variant.  Q6: Finally, April is National Minority Health Month how can I get involved? This year the U.S. Department of Health and Human Services (HHS) Office of Minority Health (OMH) and its partners are highlighting the important role community plays in helping to reduce health disparities in racial and ethnic minority and American Indian/Alaska Native groups. The theme for this year is Give Your Community a Boost!  To support COVID-19 vaccination and boosting, OMH invites you to #BoostYourCommunity by using, sharing, and attending National Minority Health Month (NMHM) resources and events with your organization, communities, and network!  If you are not insured, you might qualify for the Oregon Health Plan, which covers COVID-19 vaccines, boosters, treatment and home tests. It also covers regular check-ups, prescriptions, mental health care, addiction treatment, dental care and more. To see if you qualify and to learn more go to OHP.Oregon.gov and click Apply for OHP. You can also call 800-699-9075 or find a local community partner at bit.ly/ohplocalhelp for help.Document accessibility: For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the Health Information Center at 1-971-673-2411, 711 TTY or COVID19.LanguageAccess@dhsoha.state.or.us.

In this episode, Dr. Christopher Tookey and Dr. Rose Wolbrink talk about the two new pills for COVID; nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Veklery). We review who should think about these medications if they test postive for COVID.  A disclaimer, we're providing general guidance but everyone is different and you should always discuss with your health care professional management of any disease and therapy before trying anything you discover from a source on the internet (including this podcast). This podcast does not reflect the opinion of our employer. 

This week in COVID related news, a heartburn medication shows benefit in patients; Bebtelovimab is authroized; Veklury is shown to retain antiviral activity against variants. Away from COVID, a functionally scored carbidopa/levodopa tablet is now available for Parkinson disease, and the FDA issue a ketamine compounding warning.

Here are the links for everything discussed in Episode 75. Times are also below so feel free to skip around and get to the updates that interest you.  (1:13) Expanded EUA for Veklury (5:47) Spikevax vaccine approved by Moderna Other FDA approvals: (9:49) - Quviviq (11:13) - Enjaymo (12:34) - Felqsuvy (13:05) - Vabysmo CDC website for COVID information - get boosted!Connect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma.

Episode 80: Oral Meds for COVID-19. The US department of human health and services recently launched the COVID19 Therapeutics Locator website to allow providers find locations where they can send prescriptions for Paxlovid and Molnupiravir. Find the COVID19 therapeutics locator online: https://arcg.is/iuuW50Yasmin and Arti discuss oral medications under emergency use authorization for COVID-19: Paxlovid and Molnupiravir. Introduction: Meds for COVID-19.  By Hector Arreaza, MD.  For the last 2 years, humanity has faced the challenge to find an effective way to fight COVID-19. This pressing charge has not been free of obstacles. It has been hindered by politics, misinformation, greed, jealousy, and many other not-so positive human traits. For me, living through the pandemic has been somewhat frustrating and shaming. Stupidity, vulgarity, and mediocrity are a few of the attributes that have flourished during the last 2 years all around us. But not everything about the pandemic has been negative. Many talented people with good intentions have engaged in serious research and have made tremendous contributions to science and humanity. Vaccines have been developed using cutting-edge technology and their efficacy has been very positive so far. Many medications have been tried to fight COVID-19 since the beginning. Some clinicians have tried to repurpose old medications in their honest desires to fight COVID-19. Examples include ACE inhibitors, statins, azithromycin, hydroxychloroquine, and chloroquine, which have not proven to be effective against this virus so far. Ivermectin, for example, has been very controversial since the beginning of the pandemic. Ivermectin is not approved by the FDA for the treatment of COVID-19. Until today, the National Institutes of Health do not have enough data to recommend for or against using ivermectin for COVID-19. “Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.” Ivermectin is still being used by some clinicians in the United States based on personal experience and opinions.At this time, remdesivir (brand name Veklury®) is the only medication approved by the FDA to treat COVID-19. IV remdesivir won full FDA approval in October 2020 for hospitalized patients, and its use has been expanded a couple days ago to include use in non-hospitalized high-risk patients. The NIH recommends against IL-6 inhibitors, such as tocilizumab or sarilumab, in COVID-19 patients who are not in the ICU. At this moment, there is not enough data for the NIH to make a recommendation for patients who are in the ICU. Baricitinib is an oral medication used to treat rheumatoid arthritis authorized in November 2020 to be used in combination with remdesivir for the treatment of COVID-19 in certain hospitalized children and adults who require supplemental oxygen, mechanical ventilation, or Extracorporeal membrane oxygenation (ECMO). Baricitinib is now authorized to be used without remdesivir against COVID-19 in hospitalized patients. We cannot forget the use of dexamethasone in hospitalized patients requiring oxygen.Today we want to give you a little taste of two oral medications: Paxlovid® and molnupiravir. You will listen to two brave medical students presenting what they have found about these medications. This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it's sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. Paxlovid®.   By Yasmin Fazli, MS3, Ross University School of Medicine.  What is it?Paxlovid® is the first oral treatment for mild-to-moderate coronavirus disease (COVID-19) in patients over 12 years-old to be issued by the FDA. The FDA issued an emergency use authorization (EUA) on December 22, 2021. It is made up of two different medications: nirmatrelvir and ritonavir. Nirmatrelvir is a protease inhibitor while ritonavir helps decrease the breakdown of nirmatrelvir.  The combination authorized is nirmatrelvir 300 mg plus ritonavir 100 mg. You may remember ritonavir use in combination with other antiretrovirals for the treatment of HIV/AIDS. At the end of the 2021, Pfizer announced that results from a trial comparing between Paxlovid® versus a placebo revealed that Paxlovid® reduced proportion of mortality and morbidity by 88% compared to placebo after a 5-day course. When and how to prescribe it?To use Paxlovid® some criteria must be met by the patient. First, a positive result of COVID-19 viral testing, second, the patient must be at high risk for illness progression to a more severe state, including hospitalization and death; and third, the patient must be 12 years or older.  Paxlovid® should be started as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset. It is to be taken by mouth 2 times a day for 5 days straight with or without food. You take 3 pills twice a day. It is not authorized for more than 5 days.  It is not authorized for the pre-exposure or post-exposure prevention of COVID-19. It's not meant to be a replacement for the vaccine.  Side effects?Possible side effects of Paxlovid® include dysgeusia (altered or impaired sense of taste), diarrhea, increased blood pressure, and myalgia (muscle aches). Nirmatrelvir and ritonavir, which comprise Paxlovid®, also interact with other medications, which may lead to serious or life-threatening adverse reactions.  It's contraindicated in patients taking medications that are dependent on CYP3A metabolism for clearance, for example, warfarin, amiodarone, clozapine, midazolam, sildenafil (for pulmonary hypertension), etc. A list of these medications has been reviewed by the FDA and you can find it online.  Liver problems have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering Paxlovid® to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Furthermore, Paxlovid® is not recommended for patients with severe kidney problems, and if they do use it, the dose should be adjusted.Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. As for pregnancy or lactation, there currently is no data available for it to understand any potential effects on miscarriages, birth defects, or maternal and fetal outcomes. Considering all of this, please review your patients' list of medications and supplements and medical history prior to initiating Paxlovid®.Concerns?Due to its limited clinical data availability, other adverse effects that have not been reported may also occur while using Paxlovid® on top of the side effect list we are aware of. Ritonavir is a well-known medication, but nirmatrelvir is brand new.  Another concern is its limited availability. So even though it has shown positive results, it is not widely available yet, which leads to having to prioritize certain populations such as the unvaccinated patients. This may prove to be a moral and ethical concern.  Effectiveness?There is no long-term data on Paxlovid® yet; however, from what we do know, it is proving to be effective more than placebo by almost 90% which shows much promise. It works against current or previous variants of COVID-19.  EPIC-HR is the randomized, double-blind, 2-arm study done to prove Paxlovid®. It included 2246 patients with laboratory-confirmed SARS-CoV-2 infection, mild to moderate symptoms, and at least one comorbidity with increased risk of developing severe illness from COVID-19. Patients were randomly assigned 1:1 to receive either Paxlovid or placebo orally every 12 hours for 5 days. Results: Paxlovid significantly reduced the risk of COVID-19-related hospitalization or death from any cause by 89% (within 3 days of symptom onset) compared with placebo. Through day 28, 0.7% (5/697) of patients in the Paxlovid® arm were hospitalized compared with 6.5% (44/682) of those in the placebo arm. The study also showed that nobody died taking Paxlovid® while 12 people died taking placebo. These are promising results and Pfizer will be announcing more information on the effectiveness as time passes by.  Pricing?The original pricing was announced to be $530.00; however, it's been added that it'll be at no cost to the people in the United States.  Molnupiravir.   By Arti Patel, MS3, Ross University School of Medicine.  1. What is molnupiravir? Molnupiravir is an antiviral medication that can be used to treat COVID-19. Molnupiravir is a nucleoside analog that inhibits viral replication. The active drug of molnupiravir (N-hydroxycytidine) tricks the RNA polymerase enzyme into incorporating the drug instead of uridine or cytidine. Nucleobases continue to get added to the RNA chain and eventually the new RNA molecule has accumulated enough errors that the virus cannot replicate further.    2. When and how to prescribe it? Molnupiravir is available for Emergency Use Authorization for “mild to moderate COVID-19 disease in adults with positive results of direct viral testing who are at risk of developing severe COVID-19, including hospitalization or death or those in whom alternative COVID-19 treatment options approved by the FDA are not accessible or clinically appropriate.”  FDA provided EUA status on December 23, 2021. It should be taken as soon as COVID-19 is diagnosed, and within 5 days of symptom onset. It is not to be used as a method to prevent COVID-19 disease. Not for prophylaxis.  Benefits of treatment have not been seen after hospitalization, so administration of molnupiravir in patients hospitalized due to COVID-19 is not recommended. Adults above the age of 18 should take 800 mg orally every 12 hours for 5 days, with or without food. Use for longer than 5 days has not been studied.  3. Side effects? Most common adverse effects are diarrhea, nausea, and vomiting.  4. Concerns? Pediatric patients: Molnupiravir may not be used in patients under the age of 18 due to effects on bone and cartilage growth. Studies in rats with repeated doses of molnupiravir showed bone and cartilage toxicity.  Pregnancy: Fetal toxicity was observed when given to pregnant individuals in animal reproduction studies. Risk of adverse maternal or fetal outcomes or birth defects have not been studied in humans as of now. Use of molnupiravir in pregnant individuals may be considered once the prescribing physician has assessed the potential risks and benefits. Prior to initiating treatment of molnupiravir, if clinically indicated, assess whether a patient is pregnant. If a patient is having irregular menstrual cycles, first day last menstrual period is unknown, or patient is not using an effective method of contraception, a pregnancy test is advised.  Females of childbearing age are advised to use an effective method of contraception while under treatment of molnupiravir and for 4 days after the final dose. Effects of molnupiravir on sperm are not known, thus effective contraception must be used while under treatment of molnupiravir and for 3 months after the last dose.  Additionally, breastfeeding is not recommended during treatment and for 4 days after the last dose.  5. Effectiveness? Although molnupiravir is not substitute in patients for whom COVID-19 vaccination and booster are recommended, it can be used for treatment of non-hospitalized patients with COVID-19 who have a high risk of progression to severe disease.  In, MOVe-OUT, a randomized, double-blind, placebo-controlled clinical trial, almost 7% of about 700 individuals who received molnupiravir were hospitalized compared to almost 10% of 700 individuals who received the placebo. During the follow up period, one person who received molnupiravir died compared to 9 people who received the placebo. The safety and effectiveness of molnupiravir continues to be studied.  Availability and pricing?Not available in pharmacies yet, and preliminary pricing for a 5-day course of molnupiravir was about $700. Conclusion of episode:Now we conclude our episode number 80 “Oral Meds for COVID-19.” We hope you got enough information about these two medications: Pax-lovid and Mol-nu-pira-vir. Remember that they are authorized (not approved yet) by the FDA for the treatment of COVID-19. They are both oral medications, taken twice a day for 5 days. Their use in pregnant patients is not recommended yet. Paxlovid can be used in patients older than 12 years old, and molnupiravir in patients older than 18 years old. We'll keep learning together about these medications in the future. Even without trying, every night you go to bed being a little wiser.Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created with educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza, Arti Patel and Yasmin Fazli. Audio edition: Suraj Amrutia. See you next week! _____________________References:F.D.A. Approves Remdesivir for Patients Not Hospitalized, The New York Times, nytimes.com, January, 21, 2022, https://www.nytimes.com/2022/01/21/world/remdesivir-fda-approval-expanded-covid.html. “Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19”, U.S. Food and Drug, December 22, 2021, https://www.fda.gov/media/155052/download. Accessed on Jan 24, 2022. “Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment,” pfizer.com, December 22, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel.  Ahmad, B., Batool, M., Ain, Q. U., Kim, M. S., & Choi, S. (2021). Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International journal of molecular sciences, 22(17), 9124. https://doi.org/10.3390/ijms22179124 Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults, fda.gov, December 23, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain. Accessed on January 24, 2022. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir, fad.gov, December 23, 2021, https://www.fda.gov/media/155054/download, accessed on January 24, 2022. 

Thank you for joining us for episode 25 of OccPod, the official podcast of the American College of Occupational and Environmental Medicine. This episode, which is the first of 2022, continues the COVID Conversations series, which is dedicated to sharing the latest COVID-19 news, and frame conversations through the lens of science with a focus on OEM, or occupational and environmental medicine. In this conversation, Erin and Dr. Nabeel discuss updates to the Omicron variant and therapeutic treatments for non-hospitalized COVID-19 patients. The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19. The FDA has also issued Emergency Use Authorizations (EUAs) for several monoclonal antibody treatments for COVID-19 for the treatment, and in some cases prevention (prophylaxis), of COVID-19 in adults and pediatric patients. Monoclonal antibodies are laboratory-made molecules that act as substitute antibodies. As always, thank you for joining us for another episode of OccPod: COVID Conversations – we hope you enjoy.

This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and important info about some Veklury lots being recalled.

El 11 de noviembre de 2021. El comité de medicamentos humanos de la EMA ( CHMP ) ha recomendado autorizar Ronapreve (casirivimab / imdevimab) y Regkirona (regdanvimab) para COVID-19. Primeros anticuerpos monoclonales recomendados para autorización de comercialización. RONAPREVE. (casirivimab / imdevimab). Datos de los estudios. Un estudio principal mostró que el tratamiento con Ronapreve en la dosis aprobadas condujo a menos hospitalizaciones o muertes en comparación con el placebo. Con base a la información anterior la empresa que solicitó la autorización de Ronapreve fue Roche Registration GmbH. Ronapreve también se puede usar para prevenir COVID-19 en personas de 12 años o más que pesen al menos 40 kilogramos. REGKIRONA. (regdanvimab). Datos del estudio. Un estudio principal mostró que el tratamiento con Regkirona provocó que menos pacientes requirieran hospitalizaciones u oxigenoterapia o murieran en comparación con el placebo. Con base a la información anterior la empresa que solicitó la autorización de Regkirona fue Celltrion Healthcare Hungary Kft . CONCLUSIÓNES. Ronapreve y Regkirona son los primeros medicamentos de anticuerpos monoclonales en recibir una opinión positiva del comité de medicamentos humanos de la EMA para COVID-19 y se unen a la lista de productos COVID-19 que han recibido una opinión positiva desde que se recomendó la autorización de Veklury (remdesivir) en junio de 2020. El perfil de seguridad de ambos medicamentos fue favorable con un pequeño número de reacciones relacionadas con la perfusión, y el comité de medicamentos humanos de la EMA concluyó que los beneficios de los medicamentos son mayores que sus riesgos para los usos aprobados. REFERENCIA. https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines https://www.ema.europa.eu/en/medicines/human/EPAR/regkirona https://www.ema.europa.eu/en/medicines/human/EPAR/ronapreve ADAPTACION PARA AUDIO-OYENTES: Medicina en una página. ==================================================== PODCAST CORONAVIRUS. COVID-19 Este es un podcast en el que desde el ojo de la ciencia. Aprenderemos del coronavirus y de la enfermedad covid-19. Recuerden al enemigo es mejor conocerlo. Para acabarlo. Esta es una producción de: Medicina en una página. medicinaenunapagina@gmail.com Dirección y Conducción: John Jarbis García Tamayo. Médico y cirujano, Epidemiólogo y Pedagogo Universitario. Portada: Gracias a Sam Balye por compartir su trabajo (foto-portada) en https://unsplash.com/. Música: https://www.youtube.com/audiolibrary/music?nv=1

WARNING - Remdesivir has a proven track record of killing people. Please listen to this podcast then share it with someone you love. You may just save their life.

Hasta el día de hoy para el tratamiento específico de pacientes con COVID-19, con acción directa contra el virus SARS CoV-2. Estamos usando medicamentos antivirales, anticuerpos monoclonales e inhibidores de proteínas. En este episodio describiremos 2 tipos autorizados por la administración de Drogas y Alimentos de los EE. UU. (FDA). Por un lado, los que son aprobados y por otro lado los que son solo autorizados para uso de emergencia. Además, cuales son para pacientes hospitalizados y los que son para los pacientes no hospitalizados. Tratamientos aprobados y autorizados por las FDA. Primero: El primer tratamiento aprobado para para el tratamiento de pacientes con COVID-19, hospitalizados con síntomas de moderados a graves. Medicamento antiviral remdesivir (Veklury). Segundo: Tratamientos autorizados para uso de emergencia para el COVID-19 por la FDA. Para pacientes hospitalizados: 1- Plasma covalente COVID-19. 2- Baricitinib, en combinación con Remdesivir. Para pacientes NO hospitalizados: 1- Los anticuerpos monoclonales: Casirivimab e Imdevimab. 2- Los anticuerpos monoclonales: Bamlanivimab y Etesevimab. REFERENCIA https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-el-primer-tratamiento-para-el-covid-19 https://www.fda.gov/news-events/press-announcements/la-fda-emite-una-autorizacion-de-uso-de-emergencia-para-el-plasma-convaleciente-como-un-tratamiento https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-autoriza-una-combinacion-de-medicamentos-para-el https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0

Hasta el día de hoy para el tratamiento específico de pacientes con COVID-19, con acción directa contra el virus SARS CoV-2. Estamos usando medicamentos antivirales, anticuerpos monoclonales e inhibidores de proteínas. En este episodio describiremos 2 tipos autorizados por la administración de Drogas y Alimentos de los EE. UU. (FDA). Por un lado, los que son aprobados y por otro lado los que son solo autorizados para uso de emergencia. Además, cuales son para pacientes hospitalizados y los que son para los pacientes no hospitalizados. Tratamientos aprobados y autorizados por las FDA. Primero: El primer tratamiento aprobado para para el tratamiento de pacientes con COVID-19, hospitalizados con síntomas de moderados a graves. Medicamento antiviral remdesivir (Veklury). Segundo: Tratamientos autorizados para uso de emergencia para el COVID-19 por la FDA. Para pacientes hospitalizados: 1- Plasma covalente COVID-19. 2- Baricitinib, en combinación con Remdesivir. Para pacientes NO hospitalizados: 1- Los anticuerpos monoclonales: Casirivimab e Imdevimab. 2- Los anticuerpos monoclonales: Bamlanivimab y Etesevimab. REFERENCIA https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-el-primer-tratamiento-para-el-covid-19 https://www.fda.gov/news-events/press-announcements/la-fda-emite-una-autorizacion-de-uso-de-emergencia-para-el-plasma-convaleciente-como-un-tratamiento https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-autoriza-una-combinacion-de-medicamentos-para-el https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0

This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published. 

Crescono i timori sulla variante Delta Plus, soprattutto in India. Gli Usa lanciano un investimento miliardario per lo sviluppo di farmaci antivirali per tenere sotto controllo la pandemia. Intanto, su tutt'altro fronte, l'Italia va in soccorso delle partite Iva colpite dalla crisi pandemica con nuovi aiuti

Here are the links for everything discussed in Episode 45, I'm also including times here so feel free to skip ahead to the topics that interest you. (1:22) Approval of Veklury to treat COVID19 (8:38) Inmazeb approved for Ebola virus CDC updates on COVID-19 & influenza reportingConnect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

Tonight's Show: remdesivir Easysense is helping people and animals through the Pandemic! Guest-from Med 10000, Serina Abdul SatterNews: A thought to share- Franchisees in Central Japan. Fujitsu, SONY and EAZYSENSE are some of these Franchisees. The world knows that there is real stature about establishing a Franchisee in Tokyo. More News: Yes, protein antibodies abound but the published Broderick patents include a photosensitive possibility. and More News: From Genetic Engineering and Biotechnology News, 10/23/2020-MaryAnn Liebert Publications, New Rochelle, NY. Disclosure: Dr. Patricia A. Broderick is the former Editor-in-Chief, Journal of Caffeine Research, MaryAnn Liebert Publications, New Rochelle, NY. https://www.genengnews.com/news/gileads-remdesivir-wins-fdas-first-covid-19-drug-approval/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20201023&oly_enc_id=4125B4703801B6N Eight months after it was first tested in human patients at the center of the world's first COVID-19 outbreak, Gilead Sciences' antiviral remdesivir yesterday won the FDA's first approval of a drug against the virus—but for a smaller population than allowed under its previous emergency use authorization (EUA) from the agency. Remdesivir—to be marketed in the United States as Veklury®—will be indicated for adults and pediatric patients 12 years of age and older who have forms of COVID-19 serious enough to require hospitalization, and who weigh at least 40 kg (88 pounds).Websites: https://www.ccny.cuny.edu/profiles/patricia-broderickhttps://www.eazysensenanotechnology.comhttps://www.eazysensationalbrainimaging.comhttps://www.eazysense.com

This week on the pod: Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is 'cautiously optimistic' a vaccine could arrive before year's end; A short course of treatment for tuberculosis shows promise; Phase 3 results for a novel pneumococcal vaccine; The FDA rejects a patch intended to treat migraines; And the breaking news that remdesivir (Veklury) has gained FDA approval.